High-Mobility Group Box-1 Mediates Toll-Like Receptor 4–Dependent Angiogenesis
暂无分享,去创建一个
X. Yao | Ji Ming Wang | S. Su | Hong-yan Zhou | Qing Lin | Xialin Liu | X. Ren | Shiyou Zhou | F. Wen | X. P. Yang | D. Fang | Jiazhu Fang
[1] S. Su,et al. Production of recombinant human HMGB1 and anti-HMGB1 rabbit serum. , 2011, International immunopharmacology.
[2] Jinyue Hu,et al. The expression of functional toll‐like receptor 4 is associated with proliferation and maintenance of stem cell phenotype in endothelial progenitor cells (EPCs) , 2010, Journal of cellular biochemistry.
[3] M. Moskowitz,et al. High-Mobility Group Box 1 Promotes Metalloproteinase-9 Upregulation Through Toll-Like Receptor 4 After Cerebral Ischemia , 2010, Stroke.
[4] V. Shah,et al. Endothelial cell toll‐like receptor 4 regulates fibrosis‐associated angiogenesis in the liver , 2010, Hepatology.
[5] M. Bianchi,et al. TLR4‐mediated skin carcinogenesis is dependent on immune and radioresistant cells , 2010, The EMBO journal.
[6] S. Akira,et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release , 2010, Proceedings of the National Academy of Sciences.
[7] E. Aronica,et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures , 2010, Nature Medicine.
[8] G. Ghirlanda,et al. High-Mobility Group Box-1 Protein Promotes Angiogenesis After Peripheral Ischemia in Diabetic Mice Through a VEGF-Dependent Mechanism , 2010, Diabetes.
[9] Huan Yang,et al. Fas (CD95) induces rapid, TLR4/IRAK4-dependent release of pro-inflammatory HMGB1 from macrophages , 2010, Journal of Inflammation.
[10] J. Wang,et al. Extracellular High Mobility Group Box-1 (HMGB1) Inhibits Enterocyte Migration via Activation of Toll-like Receptor-4 and Increased Cell-Matrix Adhesiveness* , 2009, The Journal of Biological Chemistry.
[11] R. Dana,et al. Growth Factors , Cytokines , Cell Cycle Molecules Contribution of Macrophages to Angiogenesis Induced by Vascular Endothelial Growth Factor Receptor-3-Specific Ligands , 2010 .
[12] N. Mukaida,et al. Enhanced experimental corneal neovascularization along with aberrant angiogenic factor expression in the absence of IL-1 receptor antagonist. , 2009, Investigative ophthalmology & visual science.
[13] A. Sauaia,et al. HMGB1 IS MARKEDLY ELEVATED WITHIN 6 HOURS OF MECHANICAL TRAUMA IN HUMANS , 2009, Shock.
[14] T. Billiar,et al. Mechanisms of Toll-Like Receptor 4 (TLR4)-Mediated Inflammation After Cold Ischemia/Reperfusion in the Heart , 2009, Transplantation.
[15] A. Kudo,et al. High mobility group box protein-1 in experimental autoimmune uveoretinitis. , 2009, Investigative ophthalmology & visual science.
[16] Ye Wang,et al. Potential role of macrophages in experimental keratomycosis. , 2009, Investigative ophthalmology & visual science.
[17] S. Akira,et al. ROLE OF TOLL-LIKE RECEPTORS 2 AND 4, AND THE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS IN HIGH-MOBILITY GROUP BOX 1-INDUCED INFLAMMATION IN VIVO , 2009, Shock.
[18] H. Lee,et al. Toll-like receptor 4 initiates an innate immune response to lipopolysaccharide in human conjunctival epithelial cells. , 2009, Experimental eye research.
[19] Q. Gong,et al. Protective Effect of Antagonist of High‐mobility Group Box 1 on Lipopolysaccharide‐Induced Acute Lung Injury in Mice , 2009, Scandinavian journal of immunology.
[20] R. Medzhitov,et al. Toll-like receptors and cancer , 2009, Nature Reviews Cancer.
[21] M. Bianchi,et al. Induction of inflammatory and immune responses by HMGB1–nucleosome complexes: implications for the pathogenesis of SLE , 2008, The Journal of experimental medicine.
[22] N. Mukaida,et al. Essential contribution of CCL3 to alkali-induced corneal neovascularization by regulating vascular endothelial growth factor production by macrophages , 2008, Molecular vision.
[23] M. Capogrossi,et al. High-mobility group box 1 protein in human and murine skin: involvement in wound healing. , 2008, The Journal of investigative dermatology.
[24] M. Capogrossi,et al. HMGB1-stimulated human primary cardiac fibroblasts exert a paracrine action on human and murine cardiac stem cells. , 2008, Journal of molecular and cellular cardiology.
[25] R. J. Ross,et al. Immunological protein expression profile in Ccl2/Cx3cr1 deficient mice with lesions similar to age-related macular degeneration. , 2008, Experimental eye research.
[26] Arjan W. Griffioen,et al. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1) , 2008, Angiogenesis.
[27] M. Rosengart,et al. HMGB1 release induced by liver ischemia involves Toll-like receptor 4–dependent reactive oxygen species production and calcium-mediated signaling , 2007, The Journal of experimental medicine.
[28] Laurence Zitvogel,et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.
[29] C. Baudouin,et al. LPS-stimulated inflammation and apoptosis in corneal injury models. , 2007, Molecular vision.
[30] B. Huang,et al. Extracellular Hmgb1 Functions as an Innate Immune‐Mediator Implicated in Murine Cardiac Allograft Acute Rejection , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[31] E. Chavakis,et al. High-Mobility Group Box 1 Activates Integrin-Dependent Homing of Endothelial Progenitor Cells , 2007, Circulation research.
[32] Hongli Li,et al. Toll-like receptor 4 in atherosclerosis , 2007, Journal of cellular and molecular medicine.
[33] D. Pisetsky,et al. The Relationship between Apoptosis and High-Mobility Group Protein 1 Release from Murine Macrophages Stimulated with Lipopolysaccharide or Polyinosinic-Polycytidylic Acid , 2007 .
[34] M. Cancino-Diaz,et al. Lipopolysaccharide from Escherichia coli induces the expression of vascular endothelial growth factor via toll-like receptor 4 in human limbal fibroblasts. , 2006, Experimental eye research.
[35] K. Tracey,et al. HMGB1 SIGNALS THROUGH TOLL-LIKE RECEPTOR (TLR) 4 AND TLR2 , 2006, Shock.
[36] Ashok Kumar,et al. Toll-like receptors and corneal innate immunity. , 2006, Current molecular medicine.
[37] H. S. Warren,et al. Toll-like receptors. , 2005, Critical care medicine.
[38] R. Darveau,et al. MD-2 Mediates the Ability of Tetra-Acylated and Penta-Acylated Lipopolysaccharides to Antagonize Escherichia coli Lipopolysaccharide at the TLR4 Signaling Complex1 , 2005, The Journal of Immunology.
[39] K. Tracey,et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion , 2005, The Journal of experimental medicine.
[40] P. Rogalla,et al. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. , 2005, The American journal of pathology.
[41] Kevin J. Tracey,et al. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal , 2005, Nature Reviews Immunology.
[42] D. Golenbock,et al. Activation of toll-like receptor (TLR)2, TLR4, and TLR9 in the mammalian cornea induces MyD88-dependent corneal inflammation. , 2005, Investigative ophthalmology & visual science.
[43] O. Feron,et al. Innate immunity and angiogenesis. , 2004, Circulation research.
[44] Jingtai Cao,et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. , 2004, The Journal of clinical investigation.
[45] E. Abraham,et al. Involvement of Toll-like Receptors 2 and 4 in Cellular Activation by High Mobility Group Box 1 Protein* , 2004, Journal of Biological Chemistry.
[46] M. Bianchi,et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation , 2004, The Journal of cell biology.
[47] Joan W. Miller,et al. VEGF164-mediated Inflammation Is Required for Pathological, but Not Physiological, Ischemia-induced Retinal Neovascularization , 2003, The Journal of experimental medicine.
[48] K. Csaky,et al. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. , 2003, Investigative ophthalmology & visual science.
[49] J. Ambati,et al. Macrophage depletion inhibits experimental choroidal neovascularization. , 2003, Investigative ophthalmology & visual science.
[50] Stefan Joos,et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[51] T. Hisatomi,et al. The critical role of ocular‐infiltrating macrophages in the development of choroidal neovascularization , 2003, Journal of leukocyte biology.
[52] K. Tracey,et al. HMGB1 as a DNA‐binding cytokine , 2002, Journal of leukocyte biology.
[53] T. Misteli,et al. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2002, Nature.
[54] D. Golenbock,et al. Cutting Edge: The Immunostimulatory Activity of the Lung Surfactant Protein-A Involves Toll-Like Receptor 41 , 2002, The Journal of Immunology.
[55] B. Cronstein,et al. Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin. , 2002, The American journal of pathology.
[56] Carsten J. Kirschning,et al. HSP70 as Endogenous Stimulus of the Toll/Interleukin-1 Receptor Signal Pathway* , 2002, The Journal of Biological Chemistry.
[57] Noam Brown,et al. Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors , 2001, Journal of leukocyte biology.
[58] M. Goebeler,et al. Chemokines in cutaneous wound healing , 2001, Journal of leukocyte biology.
[59] T. Kislinger,et al. Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases , 2000, Nature.
[60] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.
[61] Cord Sunderkötter,et al. Macrophages and angiogenesis , 1994, Journal of leukocyte biology.
[62] K. Schulze-Osthoff,et al. Macrophage-derived angiogenesis factors. , 1991, Pharmacology & therapeutics.